Therapeutic interventions for COVID-19 : a living overview of reviews
department or school: Medicine, Faculty of
department or school: Non UBC
department or school: Population and Public Health (SPPH), School of
data provider: DSpace
degree campus: UBCV
identifier citation: Khalili M, Chegeni M, Javadi S, Farokhnia M, Sharifi H. Karamouzian, M. (12/2020)Therapeutic interventions for COVID-19: A living overview of reviews. Therapeutic advances in respiratory disease. 14:1753466620976021.
rights copyright: Authors
creator: Khalili, Malahat
creator: Chegeni, Maryam
creator: Javadi, Sara
creator: Farokhnia, Mehrdad
creator: Sharifi, Hamid
creator: Karamouzian, Mohammad
issued: 2021-07-19T21:19:14Z
issued: 2020
description: Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, but safe and effective treatment options remain unavailable. Numerous systematic reviews of varying qualities have tried to summarize the evidence on the available therapeutic interventions for COVID-19. This overview of reviews aims to provide a succinct summary of the findings of systematic reviews on different pharmacological and non-pharmacological therapeutic interventions for COVID-19. Methods: We searched PubMed, Embase, Google Scholar, Cochrane Database of Systematic Reviews, and WHO database of publications on COVID-19 from 1 December 2019 through to 11 June 2020 for peer-reviewed systematic review studies that reported on potential pharmacological or non-pharmacological therapies for COVID-19. Quality assessment was completed using A MeaSurement Tool to Assess systematic Reviews-2 (AMSTAR-2) measure. Results: Out of 816 non-duplicate studies, 45 were included in the overview. Antiviral and antibiotic agents, corticosteroids, and anti-malarial agents were the most common drug classes used to treat COVID-19; however, there was no direct or strong evidence to support their efficacy. Oxygen therapy and ventilatory support was the most common non-pharmacological supportive care. The quality of most of the included reviews was rated as low or critically low. Conclusion: This overview of reviews demonstrates that although some therapeutic interventions may be beneficial to specific subgroups of COVID-19 patients, the available data are insufficient to strongly recommend any particular treatment option to be used at a population level. Future systematic reviews on COVID-19 treatments should adhere to the recommended systematic review methodologies and ensure that promptness and comprehensiveness are balanced.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/79035
note: https://doi.org/10.1177/1753466620976021 https://doi.org/10.1177/1753466620976021Therapeutic Advances in Respiratory Diseasejournals.sagepub.com/home/tar 1Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Ther Adv Respir Dis2020, Vol. 14: 1–34DOI: 10.1177/ 1753466620976021© The Author(s), 2020. Article reuse guidelines: sagepub.com/journals-permissionsIntroductionSevere acute respiratory coronavirus 2 (SARS-CoV-2) was first detected in patients linked with Wuhan’s wet markets, but soon grew out of China and the coronavirus disease 2019 (COVID-19) was declared a pandemic on 11 March 2020.1 Healthcare systems worldwide have been over-whelmed and continue to struggle with the soar-ing number of patients, limited supplies of personal protective equipment (PPE), and venti-lators. Based on the existing evidence, the risk is relatively low for the general population, although elderly populations, immunocompromised peo-ple, and those with pre-existing medical condi-tions are at an increased risk of adverse outcomes.2,3 As of 5 October 2020, 35,330,119 COVID-19 patients have been detected, 1,038,958 of whom have died and 24,564,100 have recovered;4 figures that are most likely underestimated due to the lim-ited number of SARS-CoV-2 tests completed, inadequate confidence in the sensitivity and speci-ficity of diagnostic testing, and various systems of case reporting and recovery definitions across the world.5Therapeutic interventions for COVID-19: a living overview of reviewsMalahat Khalili , Maryam Chegeni, Sara Javadi, Mehrdad Farokhnia, Hamid Sharifi and Mohammad KaramouzianAbstractBack…
has type: Article
is shown at: 10.14288/1.0400487
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: SAGE Publications
publisher DOI: 10.1177/1753466620976021
rights: Attribution-NonCommercial-NoDerivatives 4.0 International
rights URI: http://creativecommons.org/licenses/by-nc-nd/4.0/
scholar level: Faculty
scholar level: Graduate
subject: COVID-19
subject: Pandemic
subject: Review
subject: Therapeutics
type: Text
identifier URI: http://hdl.handle.net/2429/79035